Actively Recruiting
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-02
200
Participants Needed
1
Research Sites
1095 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.
CONDITIONS
Official Title
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of neuroblastoma confirmed by pathology or bone marrow involvement with elevated urinary catecholamines
- History of tumor progression, recurrence, or failure to achieve complete response with standard therapy
- MIBG-avid neuroblastoma with evaluable disease on MIBG scan at enrollment
- At least 2 weeks since any biologic therapy and 3 weeks since last chemotherapy dose
- Age greater than 1 year
- Ability to comply with radiation safety restrictions during therapy
- For high-dose treatment, availability of autologous hematopoietic stem cells cryopreserved for reinfusion; for low-dose, not required
- Minimum peripheral blood stem cell dose of 2 x 10^6 CD34+ cells/kg if applicable
- Minimum life expectancy of eight weeks
- Signed informed consent acknowledging investigational nature
- Diagnosis of malignant pheochromocytoma or malignant paraganglioma
- MIBG-avid malignant chromaffin cell tumor with evaluable disease on MIBG scan at enrollment
- Age between 1 and 21 years for malignant chromaffin cell tumors
- Ability to cooperate with radiation safety restrictions during therapy
You will not qualify if you...
- Severe major organ toxicity greater than grade 2 for renal, cardiac, hepatic, pulmonary, gastrointestinal, or neurologic systems (grade 3 hearing deficit allowed)
- Active serious infections not controlled by antibiotics
- Pregnancy or positive pregnancy test in women of child-bearing age; contraception required during study
- Inability or unwillingness to comply with radiation safety procedures or study protocol requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
E
Ellen Basu, MD, PhD
CONTACT
S
Shakeel Modak, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here